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Noncompetitive resistanceMaraviroc binds to the pocket of extracellular loops of the cell surface CCR5 and prevents R5 HIV-1 from using
CCR5 as a coreceptor for entry into CD4-positive cells. To evaluate the contribution of the V3 loop structure in
gp120 to maraviroc resistance, we isolated maraviroc-resistant variants from the V3 loop library virus
(HIV-1V3Lib) containing a set of random combinations of 0–10 polymorphic mutations in vitro. HIV-1V3Lib at
passage 17 could not be suppressed even at 10 μM (N1400-fold resistance), while HIV-1JR-FL at passage 17
revealed an 8-fold resistance to maraviroc. HIV-1V3Lib-P17 contained T199K and T275M plus 5 mutations in the
V3 loop, I304V/F312W/T314A/E317D/I318V. The proﬁle of pseudotyped virus containing I304V/F312W/
T314A/E317D/I318V in V3 loop alone revealed a typical noncompetitive resistance, although T199K and/or
T275M could not confer noncompetitive resistance. This type of library virus is useful for isolation of escape
viruses from effective entry inhibitors.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The entry of human immunodeﬁciency virus type 1 (HIV-1) in
target cells is a feasible step where small compounds could be used to
block viral replication (Donzella et al., 1998; Dragic et al., 2000; Strizki
et al., 2001; Trkola et al., 2002). To completely suppress viral entry in
vivo, various antiviral agents have been developed that target unique
viral proteins and receptors (Kuhmann and Hartley, 2008; Tsibris and
Kuritzkes, 2007; Westby and van der Ryst, 2010). Enfuvirtide
(Fuzeon) is an antiviral peptide that prevents HIV entry by blocking
gp41-mediated fusion through interaction with the gp41 N-heptad
repeat domain to form a heterologous trimer of heterodimer complex
(Chan et al., 1997; Chan and Kim, 1998; Wild et al., 1993). Another
target to block viral entry is CCR5. Small compounds that can bind to
the pockets of the extracellular loops of CCR5 are expected to be
potent antiviral agents. Several small-molecule CCR5 inhibitors have
progressed through clinical development (Westby and van der Ryst,
2010). Maraviroc (Dorr et al., 2005; Fatkenheuer et al., 2005) is the
ﬁrst and only CCR5 antagonist approved by the U.S. Food and Drug
Administration in 2007 for treatment-experienced patients with an
R5-tropic virus.The emergence of viruses resistant to entry inhibitors as well as
other classes of antiviral agents has been reported in vitro and in vivo
(Moore and Kuritzkes, 2009; Westby and van der Ryst, 2010). The
intuitive manner of resistance to small-molecule CCR5 inhibitors
depends on coreceptor switching from a CCR5-using virus to a dual-
tropic virus or a CXCR4-using virus, but these are rare cases in vitro
and in vivo (Maeda et al., 2008; Westby and van der Ryst, 2010).
Virologic failure in clinical aspects is an outgrowth of the pre-existing
minority population of the CXCR4-using virus (Gulick et al., 2007;
Moore and Kuritzkes, 2009; Westby and van der Ryst, 2010). These
results indicate that the acquisition of the other type of resistance
occurs preferentially in R5 viruses because coreceptor switching
requires multiple mutations throughout gp160 through transitional
intermediates with poor replication ﬁtness (Pastore et al., 2004). Two
types of genetic pathways for virus escape have been reported in vitro
(Marozsan et al., 2005; Pugach et al., 2007; Trkola et al., 2002). The
ﬁrst is the accumulation of multiple amino acid substitutions in Env
including 2–4 substitutions in the gp120 V3 domain. Unique changes
have been detected in different isolates (Baba et al., 2007; Kuhmann
et al., 2004; Marozsan et al., 2005; Ogert et al., 2008; Pugach et al.,
2007; Trkola et al., 2002; Westby et al., 2007). Some of these resistant
viruses revealed noncompetitive resistance (Kuhmann et al., 2004;
Trkola et al., 2002; Westby et al., 2007). In noncompetitive resistance,
the escape variants could use the inhibitor-bound form of CCR5 as well
as free CCR5 for entry. The second is a genetic pathway independent of
V3 mutations. Resistance to vicriviroc has developed through multiple
294 Y. Yuan et al. / Virology 413 (2011) 293–299amino acid substitutions throughout gp160 without any changes in the
V3 loop (Marozsan et al., 2005). The determinants of resistance induced
by vicriviroc have been mapped on a 200-residue stretch of gp120
spanning the C2–V5 region (Ogert et al., 2008). These reports indicate
that resistance to small-molecule CCR5 inhibitors is complicated and
there appears to be no common key mutations.
In this study, we used the V3 loop library virus (HIV-1V3Lib), which
carries a set of random combinations from 0 to 10 substitutions
(27,648 possibilities) in the V3 loop (residues 302, 303, 304, 305, 306,
312, 314, 317, 318, and 321; V3 loop from Cys293 to Cys327) (Yusa
et al., 2005) (Fig. 1A). Theywere polymorphic mutations derived from
31 R5 clinical isolates. To further elucidate the contribution of the V3
loop to resistance to small-molecule CCR5 inhibitors, we selected
maraviroc-resistant variants from HIV-1V3Lib. We describe the
isolation of maraviroc-resistant variants after 17 passages with a
gradual increase in maraviroc concentration in vitro, and discuss the
ﬁnding that the resistant variants from HIV-1V3Lib revealed noncom-
petitive resistance to maraviroc.
Results
Selection of maraviroc-resistant variants from HIV-1JR-FL and HIV-1V3Lib
We used the replication-competent HIV-1V3Lib for selection of
maraviroc-resistant viruses. Each virus clone in the library contains a
set of 0–10 amino acid substitutions in the gp120 V3 loop from Cys293
to Cys327 (Fig. 1A). We used PM1/CCR5 cells for virus passages
because they have two advantages. First, PM1/CCR5 cells are highly
sensitive to the R5 virus compared to the parental PM1 cells; second,
prominent cell fusion caused by viral infection is a straightforward
sign of virus proliferation. EC50s of HIV-1JR-FL and HIV-1V3Lib to
maraviroc were 0.0069±0.0019 μM and 0.0055±0.0007 μM, respec-Fig. 1. (A) Amino acid substitutions in HIV-1V3Lib. Residues in boldface indicate the
substitutions that were randomly incorporated in HIV-1V3Lib. Underlined residues
indicate the substitutions that were not detected in 31 R5 viruses (Yusa et al., 2005).
F312C, E317H, and E317P were inevitably incorporated in HIV-1V3Lib due to
combinations of nucleotide substitutions. (B) Induction of maraviroc-resistant variants
from HIV-1V3Lib. HIV-1JR-FL and HIV-1V3Lib were passaged in PM1/CCR5 cells in the
presence of maraviroc increasing from 0.003 μM to 0.1 μM for HIV-1JR-FL and from
0.003 μM to 0.7 μM for HIV-1V3Lib.tively (Table 1). The susceptibility of HIV-1V3Lib to maraviroc was
similar to that of the wild type. To select maraviroc-resistant variants,
PM1/CCR5 cells were infected with HIV-1JR-FL or HIV-1V3Lib in the
presence of 0.003 μMmaraviroc in passage 1 (Fig. 1B). After infection,
4 to 7 days were required for the viruses to sufﬁciently replicate for
the next passage. During the passages, the concentration of maraviroc
was gradually increased up to 0.1 μM until passage 14 for HIV-1JR-FL
and HIV-1V3Lib in the same manner. At passage 15, the library virus
could replicate in 4 days in the presence of 0.2 μMmaraviroc, but the
wild type could not. The concentration of maraviroc was increased up
to 0.7 μM for HIV-1V3Lib and up to 0.1 μM for HIV-1JR-FL-P17 at passage
17.
We determined the drug susceptibilities in the passaged viruses
(Table 1).HIV-1JR-FL-P17 revealed an8-foldhigher resistance than thewild
type without drug selection. It should be noted that replication of HIV-
1V3Lib-P17 could not be blocked with even 10 μM of maraviroc, indicating
thatHIV-1V3Lib-P17wasN1449-foldmore resistant than thewild typewith
selection. HIV-1V3Lib-P17 could replicate at extremely high concentrations
of maraviroc; we designated this full resistance as complete resistance.
Furthermore, HIV-1V3Lib-P17 revealed a cross-resistance of N230-fold to
TAK-779, although HIV-1JR-FL-P17 showed only a 3.5-fold resistance
compared with the wild type without selection. These results suggested
that a certain intrinsic change occurred inHIV-1V3Lib after passage 14. The
viralﬁtness ofHIV-1JR-FL-P17 andHIV-1V3Lib-P17was comparedwith that of
viruses without selection by measuring p24 Gag in the supernatant
(Fig. 2A). Before selection with maraviroc, HIV-1V3Lib revealed lower
ﬁtness than HIV-1JR-FL. Replication of HIV-1JR-FL-P17 was almost compa-
rable to that of HIV-1JR-FL, while the viral ﬁtness of HIV-1V3Lib-P17 was
higher than that of HIV-1JR-FL or HIV-1V3Lib on day 2 or 4. These results
indicated that not only more resistant but also more ﬁtness-adapted
variants dominantly overgrew during the passages for selection.
HIV-1V3Lib did not inherently contain V3 mutants that could use
CXCR4 as a coreceptor (Yusa et al., 2005). To address whether coreceptor
switching occurred in HIV-1V3Lib-P17, MT-2 cells, which could support X4
virus HIV-1NL4-3 but not R5 virus HIV-1JR-FL (Fig. 2B), were infected with
the virus. It was clearly shown that HIV-1V3Lib-P17 could not replicate in
MT-2 cells using CXCR4, indicating that the high resistance to maraviroc
in HIV-1V3Lib-P17 was not due to coreceptor switching.Mutations in HIV-1JR-FL-P17 and HIV-1V3Lib-P17 at passage 17
To identify the mutations responsible for complete resistance to
maraviroc, we sequenced env genes at passage 10 and 17 (Table 2). At
passage 10, S303G was partially detected in HIV-1JR-FL-P10 gp120 by
direct sequencing. Actually, 2 of 4 clones of HIV-1JR-FL-P10 contained
S303G alone in the V3 loop, and no other common mutations were
detected in the other regions of gp120 and gp41 (data not shown).
Virus clones containing S303G did not become a major population
after further selection at passage 17. T314P (4 of 8 clones), S303G (2 of
8 clones), N299S (2 of 8 clones), K302E (1 of 8 clones), and A311L (1 of
8 clones) were detected in the V3 loop, indicating that the V3Table 1
Susceptibility of the viruses selected with maraviroc.
EC50a (μM)
Maravirocb TAK-779b
HIV-1JR-FL 0.0069±0.0019c (1.0) 0.043±0.009 (1.0)
HIV-1JR-FL-P17 0.055±0.0055 (8.0) 0.15±0.033 (3.5)
HIV-1V3Lib 0.0055±0.0007 (0.80) 0.025±0.007 (0.58)
HIV-1V3Lib-P17 N10 (N1400) N10 (N230)
a PM1/CCR5 cells were infected at 100 TCID50 of viruses in the presence of the CCR5
inhibitor on day 0. Cytopathic effect was determined on day 6 by MTT method.
b Drug concentration of 50% growth inhibition of the cells (CC50) was N10 μM.
c Mean±SD (n=3).
Fig. 2. Replication of HIV-1JR-FL-P17 and HIV-1V3Lib-P17 in PM1/CCR5 cells (A) or MT2 cells (B). Cells (5×104) were infected with 10 ng of p24 Gag. Viral replication was monitored by
measuring p24 Gag in the supernatant. Experiments were performed in triplicate.
295Y. Yuan et al. / Virology 413 (2011) 293–299structure was not strictly focused on the selection pressure. Instead,
T199K in the C2 region was the only mutation detected by direct
sequencing, and the mutation was conﬁrmed in 7 of 8 clones. The
mixture of these clones (HIV-1JR-FL-P17) revealed 8-fold resistance to
maraviroc (Table 1), suggesting that T199K may be a responsible
mutation for the low resistance in HIV-1JR-FL-P17.
The mutation proﬁle of HIV-1V3Lib at passage 10 was different from
that at passage 17. In passage 10, S303G (4 of 4), I306M (3 of 4), F312W
(3 of 4), T314A (3 of 4), and I322N (4 of 4) were detected in a major
population, and 1 of 4 clones contained G149R/T199A in the non-V3
region. Thus, suggesting that the low concentrations of maraviroc fromTable 2
Mutations in gp120 of V3 loop library virus selected with maraviroc.
HIV-1JR-FL -
T199K
HIV-1JR-FL-V3Lib -
T199K, T275M 
0.03
0.1
0.03
0.7
D227V
-
V267I
Y174H/T199K
L124F/V197A/T199K/E220L/S
V83L/N87Y/T199K/G442E
V83I/T199K/C436R/N452D
V83L/T199K/F378Y 
V166A/T199K/P209L/L256R/N
-
N140D/T199K
N134I/T199K/K233E
-
G149R/T199A
-
-
T199K/T275M
T199K/T275M
T199K/T275M
T199K/T262L/T275M
T199K/E208K/G219S/T262L/T
T199K/T275M
T199K/E265K/T275M
P10b
CL#01
CL#02
CL#03
CL#04
P17b
CL#01
CL#02
CL#03
CL#04
CL#05
CL#06
CL#07
CL#08
CL#01
CL#02
CL#03
CL#04
CL#01
CL#02
CL#03
CL#05
CL#06
CL#08
P10
P17
CL#04
CL#07 T199K/T262L/T275M
maraviroc (µM)  non-V3 mutations
a Amino acid residues underlined are the mutation positions in HIV-1JR-FL-V3Lib.
b P10, P17 direct sequencing was performed to detect mutations (in bold) in Env.0.003 to 0.01 μMcompelled the condensation of the V3-mutantmixture
to a small number of V3 structures. After further selection, the V3
structures detected in passage 10 were lost at passage 17, and 5
mutations in the V3 loop, I304V/F312W/T314A/E317D/I318V (desig-
nated as V3-M5) and T199K/T275M (all 8) were detected by direct
sequencing. The amino acid substitutions of V3-M5 were polymorphic
mutations inherently incorporated into the library virus. All of the
clones from HIV-1V3Lib-P17 contained these 7 common mutations,
although some of them contained minor mutations such as T262L (3
of 8). There were no other mutations detected in the other regions of
gp120 and gp41 (data not shown). HIV-1V3Lib-P17 revealed a N1400-foldCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC
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Fig. 4. The effect of 3 or 10 μM of maraviroc on the production of p24 Gag in the
recombinant viruses. Cells (5×104)were infectedwith 10 ngof p24Gag in thepresence of
3 or 10 μM of maraviroc. After 6 days, the amount of p24 Gag in the supernatant was
measured with HIV-1 p24 Gag ELISA. Mean±SD (n=3).
296 Y. Yuan et al. / Virology 413 (2011) 293–299resistance to maraviroc compared with HIV-1JR-FL (Table 1). These
results strongly suggested that T199K/T275M plus V3-M5 conferred
complete resistance to maraviroc.
Susceptibilities of recombinant viruses to maraviroc
To conﬁrmwhichmutationswere responsible for complete resistance,
we constructed molecular clones containing combinations of T199K,
T275M, and/or V3-M5, and measured their susceptibilities to maraviroc
(Fig. 3). EC50 ofHIV-1JR-FLwas0.018±0.004 μM,while thoseofHIV-1T199K
and HIV-1T275M were 0.042±0.007 μM and 0.074±0.011 μM. Thus
HIV-1T199K and HIV-1T275M were 2.3- and 4.1-fold more resistant than
HIV-1JR-FL. HIV-1T199K/T275M was 3.3-fold more resistant, indicating that
without V3mutations, T199K, T275M, or T199K/T275M could confer low
resistance, but not lead to complete resistance. On the other hand, the
V3-M5 alone could confer complete resistance to maraviroc, although its
viralﬁtnesswas lower than that ofHIV-1JR-FL (Fig. 4). p24Gagproduced in
the absence of maraviroc in HIV-1V3-M5 was 1040 pg/ml and that in
HIV-1JR-FL was 8600 pg/ml. T199K combined with V3-M5 can confer
complete resistance, and increase its viral ﬁtness. p24 Gag production in
HIV-1T199K/V3-M5 in the absenceofmaravirocwas8.5-foldhigher than that
inHIV-1V3-M5. T275Mwas detected in all 8 clones at passage 17, however,
the combination of T275M with V3-M5 resulted in marked decrease of
viralﬁtness (Fig. 4), although the viral replication could not be suppressed
by 3 or 10 μMmaraviroc. These results indicated that T275Mwith V3-M5
could confer complete resistance. T275M/V3-M5 plus T199K restored the
decreased viral ﬁtness with complete resistance. The replication of
HIV-1T199K/T275M/V3-M5 in the presence of 3 or 10 μM maraviroc was
comparable to that of HIV-1JR-FL. Taken together, V3-M5 is responsible for
the acquisition of complete resistance, and T199K and/or T275M have a
strong effect on viral replication under drug selection pressure.
Susceptibilities of pseudotyped viruses: single-round entry assay
To conﬁrm thenoncompetitive resistancemechanism,wedetermined
the susceptibilities of the recombinant viruses with a single-round entry
assay using MAGIC-5 cells (Hachiya et al., 2001). EC50 of pseudotyped
HIV-1Env-JR-FL was 0.00035±0.00007 μM. The pseudotyped viruses HIV-
1Env-T199K/T275M/V3–M5, HIV-1Env-T199K, HIV-1Env-T275M, HIV-1Env-T199K/
T275M, HIV-1Env-V3-M5, HIV-1Env-T199K/V3-M5, and HIV-1 Env-T275M/V3-M5Fig. 3. Susceptibilities of replication-competent recombinant viruses. PM1/CCR5 cells
were infected with recombinant virus at 100 TCID50 in the presence of maraviroc and
cultured for 6 days, and the cytopathic effect was determined by the MTT assay.
Susceptibility of HIV-1T275M/V3-M5 could not be examined because of its low replication.
Mean±SD (n=3).revealed a ≤3.4-fold resistance compared with HIV-1Env-JR-FL. The
competent molecular clones containing T199K/T275M/V3-M5, V3-M5,
T199K/V3-M5, and T275M/V3-M5 could not be blocked by 3 or 10 μM
maraviroc (Fig. 4), while single-round entry of these pseudotyped viruses
could be inhibited by 50% with ≤0.0012 μM of maraviroc (Table 3).
However, in thepresenceof0.1or1 μMmaraviroc, inhibitionof viral entry
could not be completely blocked (Fig. 5), indicating that the viruses could
utilize the maraviroc-bound form of CCR5. HIV-1V3-M5, HIV-1T199K/V3-M5,
and HIV-1T199K/T275M/V3-M5 retained 19, 26, and 36%, respectively, of their
entry ability at 1 μM maraviroc than those of the pseudotyped virus in
drug-free conditions. These results indicated that these viruses acquired
noncompetitive resistance by interacting with the maraviroc-binding
CCR5 complex as a second receptor.
Discussion
Maraviroc is a highly potent antiviral agent targeting CCR5 to block
the viral entry step (Kuhmann and Hartley, 2008; MacArthur and
Novak, 2008). Primary R5 isolates cultured in stimulated PBMC are
usually used to induce CCR5 inhibitor-resistant variants (Baba et al.,
2007; Kuhmann et al., 2004; Marozsan et al., 2005; Ogert et al., 2008;
Pugach et al., 2007; Trkola et al., 2002; Westby et al., 2007). Here we
used PM1/CCR5 cells with the HIV-1V3Lib constructed from a
laboratory strain to further focus on the contribution of the V3 loop
in gp120 in acquisition of maraviroc resistance. If HIV-1V3Lib originally
contained maraviroc-resistant viruses without additional mutations,Table 3
Susceptibility of recombinant viruses to maraviroc determined by single-round entry
assay.
Maraviroc
EC50a (μM)
HIV-1Env-JR-FL 0.00035±0.00007b (1.0)
HIV-1Env-T199K/T275M/V3-M5 0.00090±0.00014 (2.6)
HIV-1Env-T199K 0.00050±0.00007 (1.4)
HIV-1Env-T275M 0.00085±0.00015 (2.4)
HIV-1Env-T199K/T275M 0.00064±0.00018 (2.6)
HIV-1Env-V3-M5 0.00071±0.00022 (2.0)
HIV-1Env-T199K/V3-M5 0.0012±0.0005 (3.4)
HIV-1Env-T275M/V3-M5 0.00064±0.00021 (1.8)
a MAGIC-5 cells (2 x 104) were infected with pseudotyped virus on day 0, and 48
h postinfection luciferase activity wasmeasured to determine effective concentration of
50% entry inhibition (EC50).
b Mean±SD (n=3).
Fig. 5. Inhibition of viral entry. Pseudotyped viruses were prepared with 293T cells by transfection with pNL-luc and pCNX-FLenv. MAGIC-5 cells were infected with pseudotyped
viruses in the presence of 0.0001–1 μM of maraviroc. Mean±SD (n=3).
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wild type for selection of the virus in vitro. In reality, it tookmore than
15 passages until we obtained the resistant variants that could replicate
in the presence of ≥0.10 μM, while resistant variants could not be
isolated using HIV-1JR-FL in the same manner. The library virus
inherently confers lower viral ﬁtness in various virus clones replicating
in PM1/CCR5 cells compared to the wild type; 36% of replication-
deﬁcient virus clones (b0.5% p24 Gag generated of that of wild type on
day 6 after infection), 17% of 0.5–10% replication-competent virus
clones, 38% of 10–50% replication-competent virus clones, and 9% of
N50% replication-competent virus clones (Monde et al., 2007). From
selectionwith 0.003 to 0.1 μMfor HIV-1JR-FL, mutations including T199K
that conferred low resistance were condensed in the viral population,
and a similar condensation of variants carrying suchmutations occurred
in HIV-1V3Lib (1 of 4 clones contained T199K at passage 10). Maraviroc
from0.1 to 0.7 μM(passage 11 to 17) could suppress the proliferation of
relatively low-resistant variants and enabled the chance for a variant
containing V3-M5 combined with T199K/T275M to command a
majority of the viral population. These sequential events needed more
than 15 passages to obtain highly resistant variants.
HIV-1 V3Lib-P17 contained 5 amino acid substitutions in the V3 loop.
Wehave reported the resistant virus from the sameV3 library viruswith
TAK-779, which contained ﬁve mutations I304V/H305V/I306M/F312L/
E317D in V3 loop (Yusa et al., 2005). The TAK-779 isolated virus
revealed relatively low resistance (15-fold). Two of the ﬁve mutations,
I304V and E317D were common mutations of V3-M5, and additional
F312L, T314A and I318V in V3 loop could confer noncompetitive
resistance to maraviroc and TAK-779. A preclinical precursor of
vicriviroc AD101-resistant variants from the CC1/85 clinical isolate
revealed noncompetitive resistance, which contained 4 amino acid
substitutions–K305R (K302Rnumbering fromHV-1JR-FL gp120), H308P
(H305P), A316V (A311V), and G321E (G316E) – in the V3 region (Berro
et al., 2009; Kuhmann et al., 2004). These substitutions were not
included in the V3-M5 mutations. They introduced the 4 mutations in
the V3 region of HV-1JR-FL, but the mutant V3 did not affect AD101
susceptibility in the different context (Moore and Kuritzkes, 2009).
Another study reported that A316T (A311T numbering from HV-1JR-FL
gp120) and I323V (I318V) were particularly inﬂuential on resistance to
vicriviroc (Westby et al., 2007). I323V (I318V) was also included in the
V3-M5 mutations in HIV-1V3Lib-P17. It has been proposed that the
multiple mutations at both sides of the V3 loop in vicriviroc-resistant
HIV-1 CC101.19 decreased interactions between the V3 tip and the
secondextracellular loop (ECL2)of CCR5 and interactionswith theCCR5
N-terminus were enhanced (Berro et al., 2009). Similarly vicriviroc-
resistant HIV-1 subtype C carried K305R (K302R numbering from
HV-1JR-FL gp120), S306P (S303P), T307I (T304I), F318I (F313I), T320R(T315R), G321E (G316E) andH330Y (H326Y) accumulated sequentially
on both sides of the V3 stem; particularly incorporation of S306P and/or
K305R is crucial for efﬁcient usage of the compound-CCR5 complex
(Henrich et al., 2010; Tsibris et al., 2008). In HIV-1 subtype D, Q315E
(Arg308 in HV-1JR-FL gp120) and R321G (Glu315) are essential for
resistance to vicriviroc, which is supposed to inﬂuence interaction of
gp120 with both the N-terminus and the ECL-2 region of CCR5 (Ogert
et al., 2010). Our results also revealed that 5 amino acid substitutions at
both sides of the V3 stem could confer noncompetitive resistance,
conceivably throughmodiﬁed interactions of the V3 loopwith the ECL2
and the N-terminus of CCR5. Further experiments are necessary to
elucidate the contribution of each amino acid substitutions of V3-M5 for
noncompetitive resistance.
HIV-1V3-M5, HIV-1T199K/V3-M5, and HIV-1T199K/T275M/V3-M5 displayed
full resistance with maximum concentration of maraviroc (10 μM),
suggesting noncompetitive resistance (Pugach et al., 2007; Westby
et al., 2007). In the case of noncompetitive resistance, the inhibitor
concentration no longer has any further inhibitory effect on viral
replication. The escape variant uses the inhibitor-bound form of CCR5
for entry, aswell as a free receptor usually with lower efﬁciency. Single-
entry assays with the three pseudotyped viruses showed that 19–36%
viral entry activity was retained at 1 μM of maraviroc. HIV-1T199K/V3-M5
could use the maraviroc-bound form of CCR5 with 26% of efﬁciency,
whereas HIV-1T199K/T275M/V3-M5 could use it with 36% efﬁciency,
indicating that T199K/T275Mwith V3-M5 ﬁnally prevailed for selection
at passage 17. These results indicate that V3-M5 mutations alone can
confer complete resistance, and non-V3 mutations like T199K and/or
T275M in the C2 domain intensively modify viral ﬁtness.
In these experiments, we obtained a combination of multiple
mutations in the V3 loop containing V3-M5, I304V/F312W/T314A/
E317D/I318V from HIV-1V3Lib. Other types of V3 mutations in
combination with non-V3 mutations may be selected to support
their viral ﬁtness. To test this possibility, we may be able to select
various combinations of V3 mutants from a V3 library constructed
with HIV-1T199K or HIV-1T199K/T275M as a vector. We could not fully
explain the condition of the V3 structure that confers noncompetitive
resistance. To address this question, further studies involving the
analysis of mutants containing various combinations of mutations in
the V3 loop are necessary.
Materials and methods
Cells and viruses
PM1/CCR5 cells were generated from the human CD4+ T-cell line
PM1 (Lusso et al., 2005) by standard retrovirus-mediated transduction
298 Y. Yuan et al. / Virology 413 (2011) 293–299with pG1TKneo-CCR5 (Maeda et al., 2000). The cellsweremaintained in
RPMI1640 (Invitrogen) supplemented with 10% heat-inactivated fetal
calf serum (FCS; Vitromex). MAGIC-5 cells (HeLa-CD4+-CCR5+-LTR-ß-
galactosidase) (Hachiya et al., 2001), used as reporter cells for HIV-1
infection, and293Tcellsweremaintained inDulbecco'smodiﬁedEagle's
medium (ICN Biomedicals) supplemented with 10% heat-inactivated
FCS.
For construction of the viral competent library of pJR-FLV3Lib, 176-bp
V3-loop DNA fragments containing 0–10 random combinations of
amino acid substitutions were introduced in pJR-FL, as previously
described (Yusa et al., 2005). For virus preparation, 293T cells (2×106)
were transfected with 10 μg of pJR-FL or pJR-FLV3Lib using the calcium
phosphate ProFectionMammalian Transfection System (Promega). The
supernatant was collected 28 h after transfection, ﬁltered through a
0.22-μm ﬁlter (Millipore), and stored at −80 °C until further use. p24
Gag in the supernatant was measured using a p24 Gag ELISA
(Zeptometrix).
Selection of maraviroc-resistant variants
Maraviroc was provided by the NIH AIDS Research and Reference
Reagent Program, Division of AIDS National Institute of Allergy and
Infectious Diseases. For selection of maraviroc-resistant viruses,
5×105 of PM1/CCR5 cells were infected with 300 ng of p24 Gag in
passage 1. After washing twice with phosphate-buffered saline (PBS),
the infected cells were incubated with 0.003 μM of maraviroc at 37 °C
in 5% CO2. Virus passages were performed at 4- to 7-d intervals using
1×105 PM1/CCR5 cells from passage 2 to 17 in the presence of
maraviroc gradually increasing up to 0.7 μM for HIV-1V3Lib and 0.1 μM
for HIV-1JR-FL at passage 17.
Sequencing
The nucleotide sequences of env genes in the virus selected with
maraviroc at passage 10 and 17 were determined as follows. The virus
mixture was precipitated and subjected to reverse transcription-PCR
using the ImProm-II Reverse Transcription System (Promega). A
2.5-kb fragment of the env gene including a viral envelope-encoding
sequence in 50 μl reaction volume consisting of 50 mM KCl, 10 mM
Tris–HCl (pH 8.3), 2 mM MgCl2, 0.01% gelatin, and 2 U AmpliTaq
(Applied Biosystems Inc.) was ampliﬁed by PCR with primers JREnvF1
(5′-GAGAGAGAGCAGAAGACAGTGGCAATGA-3′) and JREnvR2 (5′-
CACTACGTTTTGACCACTTGCCACCCA-3′). For direct sequencing, a
1/100 volume of the ﬁrst PCR mixture was ampliﬁed with primers
tagged with M13 tails, and the products were puriﬁed using a PCR
puriﬁcation kit (Marlingen). Then, the second batch of PCR products
was used as the sequencing template. To sequence the virus clones,
the ﬁrst PCR products were puriﬁed by 1% agarose electrophoresis and
subcloned in the pCR-TOPO vector (Invitrogen). The cloned DNA was
sequenced using an ABI Prism 310 (Applied Biosystems Inc.).
Determination of drug susceptibilities
Susceptibilities of the viruses to the entry inhibitor was deter-
mined by the MTT assay using PM1/CCR5 cells for replication-
competent viruses as previously described (Pauwels et al., 1988).
Susceptibilities in the single-round viral entry assay were determined
using previously titrated pseudotyped virus preparations using
MAGIC-5 cells. Brieﬂy, MAGIC-5 cells were plated in 48-well tissue
culture plates 1 day prior to infection. After absorption of the
pseudotyped virus for 2 h at 37 °C in the presence or absence of
0.0001–10 μM maraviroc, the cells were washed twice with PBS, and
then further incubated for 48 h in the presence or absence of the
inhibitor in fresh medium. EC50 was determined by measuring
luciferase activity.Acknowledgments
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